SCHEMBL538747

SCHEMBL538747

CCCCCCCCCCCCCCCCCCOC1CC(COc2ccc3c(c2)C(O)(c2ccc(Cl)cc2)c2ccccc2-3)CC(OCCCCCCCCCCCCCCCCCC)C1OCCCCCCCCCCCCCCCCCC

nearest known ligand 0.46

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 19/20 0.46
PTPN11 Q06124 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31655744 1.00 PDK2 (0.46) PDK2PTPN11
SCHEMBL13165948 0.92 PDK2 (0.45) PDK2PTPN11
SCHEMBL31655745 0.88 PDK2 (0.41) PDK2PTPN11
SCHEMBL538850 0.88 PDK2 (0.41) PDK2PTPN11
SCHEMBL538738 0.84 PDK2 (0.61) PDK2PTPN11
SCHEMBL538807 0.78 PDK2 (0.56) PDK2
SCHEMBL15470839 0.76 PDK2 (0.54) PDK2
SCHEMBL538782 0.75 MAPT (0.46) PDK2PTPN11
SCHEMBL1305002 0.73 PDK2 (0.60) PDK2PTPN11
SCHEMBL28262297 0.73 PDK2 (0.60) PDK2PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220041648-A1 METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY AJINOMOTO CO., INC. (JP) 2022-02-10 US claimed
US-9029504-B2 Fluorene compound AJINOMOTO CO., INC. (JP) 2015-05-12 US claimed
US-20140046022-A1 FLUORENE COMPOUND AJINOMOTO CO., INC. (JP) 2014-02-13 US claimed
EP-2415744-A1 FLUORENE COMPOUND Ajinomoto Co., Inc. (JP) 2012-02-08 EP claimed
US-20100240867-A1 FLUORENE COMPOUND AJINOMOTO CO. INC. (JP) 2010-09-23 US claimed
US-12351601-B2 Method for producing peptide continuously AJINOMOTO CO., INC. (JP) 2025-07-08 US disclosed
US-20220041648-A1 METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY AJINOMOTO CO., INC. (JP) 2022-02-10 US disclosed
US-9334302-B2 Method for removing FMOC group AJINOMOTO CO., INC. (JP) 2016-05-10 US disclosed
US-9029504-B2 Fluorene compound AJINOMOTO CO., INC. (JP) 2015-05-12 US disclosed
US-9029504-B2 Fluorene compound AJINOMOTO CO., INC. (JP) 2015-05-12 US disclosed
US-20140296483-A1 METHOD FOR REMOVING FMOC GROUP AJINOMOTO CO., INC. (JP) 2014-10-02 US disclosed
US-20140046022-A1 FLUORENE COMPOUND AJINOMOTO CO., INC. (JP) 2014-02-13 US disclosed
US-20140046022-A1 FLUORENE COMPOUND AJINOMOTO CO., INC. (JP) 2014-02-13 US disclosed
US-8569453-B2 Fluorene compound AJINOMOTO CO., INC. (JP) 2013-10-29 US disclosed
US-8569453-B2 Fluorene compound AJINOMOTO CO., INC. (JP) 2013-10-29 US disclosed
EP-2415744-A1 FLUORENE COMPOUND Ajinomoto Co., Inc. (JP) 2012-02-08 EP disclosed
US-20100240867-A1 FLUORENE COMPOUND AJINOMOTO CO. INC. (JP) 2010-09-23 US disclosed
US-20100240867-A1 FLUORENE COMPOUND AJINOMOTO CO. INC. (JP) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220041648-A1 METHOD FOR PRODUCING PEPTIDE CONTINUOUSLY VIP, NPPA, NGLY1 PDK2 4375/4885PTPN11 2516/4885
US-20140046022-A1 FLUORENE COMPOUND NPPA, FURIN, SFPQ PDK2 3174/4885PTPN11 4108/4885
US-20140296483-A1 METHOD FOR REMOVING FMOC GROUP ESD, HM13, FURIN PDK2 4173/4885PTPN11 4598/4885
US-20100240867-A1 FLUORENE COMPOUND NPPA, FURIN, SFPQ PDK2 3174/4885PTPN11 4108/4885
US-12351601-B2 Method for producing peptide continuously VIP, NPPA, NGLY1 PDK2 4375/4885PTPN11 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.